Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,355.8
-4.2 (-0.13%)

 

  • STI Straits Times Index
    3,355.8
    -4.2 (-0.13%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,665.9
    -3.0 (-0.18%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,619.6
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,937.6
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,383.2
    -152.0 (-0.71%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,401.9
    -
    Index delayed 10 minutes
  • KOR KOSPI
    2,065.2
    -26.7 (-1.28%)
    Index delayed 20 minutes
  • XAO XAO
    6,754.1
    18.3 (0.27%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 92.0M
  • Value: 157.1M
  • Rise: 53
  • Fall: 78
  • Unch: 706

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sen Yue0.040+0.007
YZJ Shipbldg SGD1.510-0.010
SingTel3.520-
G Invacom^0.133-
Tritech0.030+0.003
Libra0.030+0.002
Miyoshi0.044+0.002
Kep Infra Tr0.505+0.005
Sino Grandness0.046-0.001
Winas0.032+0.001

World Indices

World Indices
Name Last Change
Nasdaq 8,222.8 -35.4
HSI 28,619.6
HSCEI 10,865.5
Jakarta 6,401.9
Nikkei 225 21,394.1 -141.1
SSE Comp 2,937.6
Shanghai A 3,076.8
Shanghai B 290.7
ShenZhen A 1,643.8
ShenZhen B 978.3
Taiwan W 10,830.4 -55.7
PSE Comp 0.0
KOSPI 2,063.7 -28.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS
Updated on 16 Jul 2019 (End of trading day)
Last (USD): 15.950 Change: -0.150 High: 16.965 Remarks: -
Change (%): -0.93 Low: 15.720
Open 16.030 Yesterday's Close 16.099999999999998
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 228,447 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.99815 Trailing EPS (USD) e -0.99815 NAV (USD) b 4.8443
PE a - Trailing PE f - Price / NAV b 3.2925
Dividend (USD) d - Cash In Hand (USD) g 4.1891 Issued & Paid-up Shares c 44,977,000
Dividend Yield (%) d - Price / Cash In Hand g 3.808 Treasury Shares h -
Beta - 75 Daysi 0.635 R-Squared - 75 Days(%)i 1.16 Market Cap (M) 717.383
Beta - 500 Daysi 0.586 R-Squared - 500 Days (%)i 1.78 Enterprise Value (M) 528.969
Piotroski F Score 2 Exchange Code AUTL Par Value ( $ ) n.a.
52 Weeks Volatility (%) 90.66 Free Float (%) -
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 16 May 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 14 Jun 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS NASDAQ 717.383 - - 3.2925 -
Industry Biotechnology NASDAQ 2,271.154 130.047 99.498 5.4187 0.783
Local Peer AMGEN INC NASDAQ 108,245.342 12.896 13.405 9.9931 3.071
Local Peer GILEAD SCIENCES INC NASDAQ 85,118.226 15.604 14.446 3.8777 3.434
Local Peer CELGENE CORP NASDAQ 64,552.448 15.955 13.604 7.9060 -
Local Peer BIOGEN INC NASDAQ 44,895.924 10.133 9.621 3.2463 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 45,118.275 21.522 20.938 9.5523 -
Local Peer ILLUMINA INC NASDAQ 44,438.100 53.799 52.219 11.1514 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,712.794 13.383 13.476 3.4636 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,540.788 354.910 66.140 2.8373 -
Local Peer INCYTE CORPORATION NASDAQ 17,129.387 156.443 67.720 8.2133 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 14,750.078 - - 5.0228 -
Local Peer EXACT SCIENCES CORP NASDAQ 14,844.528 - - 19.1064 -
Local Peer SAREPTA THERAPEUTICS INC NASDAQ 11,364.101 - - 8.4268 -
Other Local Peers ARRAY BIOPHARMA INC (NASDAQ), SEATTLE GENETICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), TILRAY INC (NASDAQ), REPLIGEN CORP (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ACCELERON PHARMA (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), OPKO HEALTH INC (NASDAQ), ALECTOR INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), EPIZYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), RETROPHIN INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), MACROGENICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), PERSONALIS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CYTOKINETICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), DERMIRA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), AVROBIO INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), RESTORBIO INC (NASDAQ), IMMUNOGEN INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), MERUS B V (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), SYNLOGIC INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), KAMADA (NASDAQ), ATHERSYS INC (NASDAQ), GERON CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), CHIASMA INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), AFFIMED N V (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), CHIMERIX INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ARDELYX INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), IMV INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), CUE BIOPHARMA INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), TOCAGEN INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SESEN BIO INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), NANTKWEST INC (NASDAQ), INMUNE BIO INC (NASDAQ), VERASTEM INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TREVENA INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), EQUILLIUM INC (NASDAQ), SAVARA INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VERMILLION INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), INFLARX N V (NASDAQ), CURIS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), OTONOMY INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), ORGENESIS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ARAVIVE INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), IVERIC BIO INC (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), ZAFGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), CONTRAFECT CORP (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), BIOCEPT INC (NASDAQ), HISTOGENICS CORP (NASDAQ), PRECIPIO INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOLIGENIX INC (NASDAQ), VICAL INC (NASDAQ), ATYR PHARMA INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), OHR PHARMACEUTICAL INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ADVAXIS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), VAXART INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), NEURALSTEM INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), OPGEN INC (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ)
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 100,864.210 45.204 41.403 14.6345 1.024
Global Peer AGILENT TECHNOLOGIES INC NYSE 22,103.710 69.949 19.788 4.3129 0.857
Global Peer SINO BIOPHARM HKEx 110,266.306 10.291 10.563 3.1811 0.835
Global Peer WUXI BIO HKEx 92,063.644 123.260 123.260 10.0994 -
Global Peer BEIGENE HKEx 57,100.246 - - 4.5214 -
Global Peer 3SBIO HKEx 35,125.006 23.219 23.219 3.5756 -
Global Peer Lonza SGX 5,937.453 7.663 7.663 0.6889 4.766
Global Peer GENSCRIPT BIO HKEx 33,476.940 201.320 201.327 8.9330 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,230.760 35.578 53.510 2.2590 -
Other Global Peers HAOHAI BIOTEC (HKEx), FRONTAGE (HKEx), VIVA BIOTECH (HKEx), ASCLETIS-B (HKEx), MYOVANT SCIENCES LTD (NYSE), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), MESOBLAST LTD (ASX), ESSEX BIO-TECH (HKEx), NEXT SCIENCE LTD (ASX), LEE'S PHARM (HKEx), ARCUS BIOSCIENCES INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), KADMON HLDGS INC (NYSE), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), STANDARD DIVERSIFIED INC (NYSE American), ENZO BIOCHEM INC (NYSE), PALATIN TECHNOLOGIES INC (NYSE American), PFENEX INC (NYSE American), BBI LIFE SCI (HKEx), BIOTIME INC (NYSE American), HEMISPHERX BIOPHARMA INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), CYNATA THERAPEUTICS LTD (ASX), UNI-BIO GROUP (HKEx), PORT (SET), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), IMMUTEP LTD (ASX), REGENT PACIFIC (HKEx), CT ENTERPRISE (HKEx), ORTHOCELL LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PHYLOGICA LIMITED (ASX), ZELDA THERAPEUTICS LTD (ASX), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), IMUGENE LIMITED (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), RHINOMED LIMITED (ASX), BIOSINO BIO-TEC (HKEx), ONCOSIL MEDICAL LIMITED (ASX), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), MEMPHASYS LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), PATRYS LIMITED (ASX), BIONOMICS LTD (ASX), NANOVIRICIDES INC (NYSE American), ANTEO DIAGNOSTICS LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), IMMURON LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), CELLMID LIMITED (ASX), REGENEUS LTD (ASX), GENETIC TECHNOLOGIES (ASX), BIOXYNE LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), Suntar Eco-City^ (SGX), HOLISTA COLLTECH LIMITED (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), BENITEC BIOPHARMA LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), ANATARA LIFESCIENCES LTD (ASX), HAO WEN HLDGS (HKEx), MGRC (Bursa), ACTINOGEN MEDICAL LTD (ASX), QT Vascular (SGX), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NOVITA HEALTHCARE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), MEDIBIO LIMITED (ASX), BPH ENERGY LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.770
-4.61 %
10 Days --0.120
-0.75 %
20 Days --1.250
-7.27 %
Medium Term Return 3 Months --10.950
-40.71 %
6 Months --16.050
-50.16 %
1 Year --5.820
-26.73 %
Annualised Return Annualised --
-26.73 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 14.800 - 53.240 Change From 1 Year Low +1.150 % Change From 1 Year Low (%) +7.77
Change From 1 Year High -37.290 % Change From 1 Year High (%) -70.04
2 Years Range 14.800 - 53.240 Change From 2 Years Low +1.150 % Change From 2 Years Low (%) +7.77
Change From 2 Years High -37.290 % Change From 2 Years High (%) -70.04
5 Years Range 14.800 - 53.240 Change From 5 Years Low +1.150 % Change From 5 Years Low (%) +7.77
Change From 5 Years High -37.290 % Change From 5 Years High (%) -70.04
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Historical Price Data

Date Open High Low Close Volume VWAP
15 Jul 2019 16.180 16.280 15.340 16.100 51,929 -
12 Jul 2019 15.820 16.240 15.350 16.010 66,212 -
11 Jul 2019 16.460 16.460 15.610 15.980 69,661 -
10 Jul 2019 16.880 16.880 15.600 16.090 309,079 -
09 Jul 2019 15.850 19.340 15.520 16.720 428,555 -
08 Jul 2019 16.690 16.690 15.210 16.080 112,801 -
05 Jul 2019 16.490 17.080 16.090 16.540 71,370 -
03 Jul 2019 16.060 16.570 15.360 16.330 53,234 -
02 Jul 2019 16.450 16.900 15.550 16.070 116,663 -
01 Jul 2019 16.460 17.300 16.000 16.520 192,630 -
28 Jun 2019 15.640 16.710 15.286 16.100 78,092 -
27 Jun 2019 15.400 15.840 14.800 15.530 89,018 -
26 Jun 2019 15.960 16.200 14.811 15.100 75,313 -
25 Jun 2019 15.970 16.545 15.730 15.900 57,403 -
24 Jun 2019 16.250 16.290 15.325 15.930 100,477 -
21 Jun 2019 16.470 17.080 15.960 16.320 191,308 -
20 Jun 2019 16.640 17.135 16.400 16.700 164,948 -
19 Jun 2019 17.280 17.280 15.920 16.640 104,627 -
18 Jun 2019 16.180 17.340 15.910 17.200 245,217 -
17 Jun 2019 15.650 16.020 15.090 15.860 317,428 -
14 Jun 2019 16.000 16.210 15.410 15.410 80,915 -
13 Jun 2019 16.050 16.560 15.700 16.060 87,089 -
Summary
Current 2 Weeks
(01 Jul 2019 to 15 Jul 2019)
16.460 19.340 15.210 16.100 1,472,134 -
Previous 2 Weeks
(17 Jun 2019 to 28 Jun 2019)
15.650 19.340 15.090 16.100 1,423,831 -
4 Weeks from
(17 May 2019 to 14 Jun 2019)
23.000 23.800 15.210 15.410 2,388,303 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.